According to the research report titled ‘Global Induced Pluripotent Stem Cells (iPSC) Market 2022-2028’, available with Market-Study-Report, global induced pluripotent stem cells (IPSC) market accounted for USD 2,474 million in 2021 and is expected to account for USD 4,185 million in valuation by the year 2028, exhibiting a 7.8% CAGR during the review period.

The increasing prevalence of chronic disorders, technological breakthroughs, rising geriatric population, and surging disposable income are some of the prominent factors that are driving the growth of global induced pluripotent stem cells (IPSC) market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4973410/

For the uninitiated, induced pluripotent stem cells (iPSCs) are derived from adult somatic cells that have undergone genetic reprogramming to resemble embryonic stem cells (ESCs) by being forced to express specific genes and factors that are crucial for maintaining the ES cells' distinctive characteristics.

Notably, the research report on ‘global induced pluripotent stem cells (IPSC) market’ provides vital information pertaining to the growth drivers, challenges & limitations, and other revenue prospects that are impacting the growth trajectory of this business vertical. It also offers a comparative analysis of the historical and the current market trends as well as the impact of the COVID-19 crisis on the overall industry growth.

A comprehensive assessment of the various market segments, such as the reprogramming method, function type, and application landscape has also been encompassed in the study. Moreover, the report also talks about the regional reach as well as the competitive arena of this business sphere.

Based on the reprogramming method, the market is divided into integrated and integration-free segments. Among these, the integration-free segment is likely to account for the largest share in global induced pluripotent stem cells market by the end of the study period.

Moving on to the function type, the industry is fragmented in terms of molecular and cellular engineering, cellular reprogramming, cell differentiation, cell culture, and cell analysis. In terms of the application landscape, the market is segmented into regenerative medicine, toxicity screening, drug development and discovery, and academic research.

The regional segmentation of this business space extends to Asia Pacific, North America, Europe, and the rest of the world.

ViaCyte Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., ReproCELL USA Inc., Ncardia Services B.V., Merck KGaA, Lonza Group AG, FUJIFILM Cellular Dynamics Inc. (FCDI), Fate Therapeutics Inc., Axol Bioscience Ltd., and Allele Biotechnology and Pharmaceuticals Inc. are the prominent companies in global induced pluripotent stem cells industry landscape.